Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

MannKind Corp

+ Add to Watchlist

NNF1:GR

5.925 EUR 0.217 3.53%

As of 13:03:42 ET on 02/27/2015.

Snapshot for MannKind Corp (NNF1)

Open: 6.025 Day's Range: 5.893 - 6.110 Volume: 940
Previous Close: 6.142 52wk Range: 2.786 - 9.331 1-Yr Rtn: +32.64%

Stock Chart for NNF1

No chart data available.
  • NNF1:GR 5.930
  • 1D
  • 1M
  • 1Y
6.142
Interactive NNF1 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NNF1

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.3300
Est. PEG Ratio -
Market Cap (M EUR) 2,403.77
Shares Outstanding (M) 405.70
30 Day Average Volume 2,518
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NNF1

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NNF1

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System.

Alfred E MannChairmanHakan S EdstromPresident/CEO
Juergen A MartensChief Operating OfficerMatthew J Pfeffer "Matt"VP/CFO/Investor Relations
More Company Profile & Key Executives for NNF1

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil